benefits of glp-1 agonists Frontiers The expanding benefits of GLP-1
Description
Market analysts expect the demand for these drugs to continue to grow significantly, with the global market size forecast to reach between $75bn to $140bn (2030+)
As analyzed by the recent meta-analysis of these trials, there is a 32% prevalence of heart-related diseases in T2DM patients
Patients who experience intolerable side effects at any dose can remain at their current level longer before titrating upward
When compared to controls, the two drugs efficiently reduced glycemia and weight in T2D, obesity, or both
Januvia [package insert]
Figure 33: Photograph of Jean-Pierre Raufman, credit: University of Maryland and photograph of Jonn Eng, credit: University of Buffalo
